Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC

Kilickap, S.Sezer, A.Gumus, M.Bondarenko, I.Ozguroglu, M.Gogishvili, M.Turk, H. M.2024-06-122024-06-1220211556-08641556-1380https://hdl.handle.net/20.500.14551/22770[Abstract Not Available]eninfo:eu-repo/semantics/closedAccessNon-Small Cell Lung CancerAnti-PD-1CemiplimabClinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLCConference Object163S101S101Q1WOS:000631349600072